161 related articles for article (PubMed ID: 19297267)
1. Antimicrobial susceptibility among bacterial isolates from ICU and non-ICU setting and different age groups: results from the tigecycline evaluation and Surveillance trial in North America.
Low DE; Markovic MJ; Dowzicky MJ
J Chemother; 2009 Feb; 21(1):16-23. PubMed ID: 19297267
[TBL] [Abstract][Full Text] [Related]
2. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Dowzicky MJ; Park CH
Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Vega S; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
Bertrand X; Dowzicky MJ
Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
[TBL] [Abstract][Full Text] [Related]
5. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.
Namdari H; Tan TY; Dowzicky MJ
Int J Infect Dis; 2012 Jan; 16(1):e60-6. PubMed ID: 22104303
[TBL] [Abstract][Full Text] [Related]
6. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014.
Marco F; Dowzicky MJ
J Glob Antimicrob Resist; 2016 Sep; 6():50-56. PubMed ID: 27530839
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
Balode A; Punda-Polić V; Dowzicky MJ
Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Zhang Z; Chen M; Yu Y; Pan S; Liu Y
Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
Kanj SS; Whitelaw A; Dowzicky MJ
Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
[TBL] [Abstract][Full Text] [Related]
12. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
Dowzicky MJ; Chmelařová E
Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
[TBL] [Abstract][Full Text] [Related]
13. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.
Morfin-Otero R; Dowzicky MJ
Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
Morfin-Otero R; Noriega ER; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
Fernández-Canigia L; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2012 Oct; 11():29. PubMed ID: 23088592
[TBL] [Abstract][Full Text] [Related]
17. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.
Chen YH; Lu PL; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
Antimicrob Agents Chemother; 2012 Mar; 56(3):1452-7. PubMed ID: 22203598
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study.
Seifert H; Blondeau J; Dowzicky MJ
Int J Antimicrob Agents; 2018 Oct; 52(4):474-484. PubMed ID: 30012439
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2011-2016.
Dowzicky MJ; Chmelařová E
J Glob Antimicrob Resist; 2019 Jun; 17():44-52. PubMed ID: 30445209
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010-2014.
Tärnberg M; Nilsson LE; Dowzicky MJ
Int J Infect Dis; 2016 Aug; 49():141-8. PubMed ID: 27343986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
